Clinical trials
Multiple Sclerosis trials in Canada with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
51 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2010 | 2 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 3 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 5 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 28 |
| Unknown status | 10 |
| Recruiting | 4 |
| Not yet recruiting | 4 |
| Terminated | 2 |
| Active, not recruiting | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sunnybrook Health Sciences Centre | 4 |
| University of Saskatchewan | 4 |
| Brock University | 3 |
| McMaster University | 3 |
| The Hospital for Sick Children | 3 |
| University of Alberta | 3 |
| University of Ottawa | 3 |
| Hicks, Audrey, Ph.D. | 2 |
| Memorial University of Newfoundland | 2 |
| Robert Simpson | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Sclerosis | 51 |
| Fatigue | 4 |
| Spinal Cord Injuries | 4 |
| Anxiety Disorders | 3 |
| Mobility Limitation | 3 |
| Multiple Sclerosis, Chronic Progressive | 3 |
| Stroke | 3 |
| Inflammation | 2 |
| Brain Injuries | 1 |
| Cognition Disorders | 1 |
Trials
Showing 1 to 25 of 51. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.